HHS, FDA Commend DEA Action Against Dangerous Enhanced 7-OH Products - Takeaways - MDSpire

HHS, FDA Commend DEA Action Against Dangerous Enhanced 7-OH Products

  • By

  • Assistant Secretary for Public Affairs (ASPA)

  • July 1, 2026

  • 0 min

Share

  • 1

    HHS and FDA praised the DEA's initiative to regulate certain kratom-related substances, including 7-OH and its synthetic derivatives.

  • 2

    The DEA issued Notices of Intent to temporarily schedule 7-OH and three synthetic derivatives in Schedule I of the Controlled Substances Act.

  • 3

    The Office of the Assistant Secretary for Health requested public comments on the proposed threshold level for 7-OH to assess public safety risks.

  • 4

    MP, MGM-15, and MGM-16 are synthetic derivatives of 7-OH that do not occur naturally in the kratom plant and pose health risks.

  • 5

    The actions are part of the Trump Administration's efforts to combat the opioid epidemic and protect public health from dangerous substances.

Original Source(s)

HHS, FDA Commend DEA Action Against Dangerous Enhanced 7-OH Products

  • by Assistant Secretary for Public Affairs (ASPA)

  • July 1, 2026

Related Content

Side Effects: Context Is the Diagnosis

This week's research makes one thing clear: who someone is before they get sick — their relationships, their partner's health, the back of their eye — is doing a lot of work medicine is only beginning to account for.

Side Effects: The Hidden Variable

The partner in the next room, the hormone in the blister pack, the cat on the couch, the minute-long chair stand. Several new studies suggest the factor shaping outcomes may be the one clinicians aren’t routinely measuring.

Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial